Iovance Biotherapeutics is a biotechnology company that develops cancer immunotherapy products which harness the immune system to eliminate cancer cells. The company has six ongoing phase 2 clinical studies focusing on its lead product candidate, lifileucel, for treatments of metastatic melanoma, recurrent cervical cancer, and head and neck squamous cell carcinoma. Established in 2007, Iovance Biotherapeutics is headquartered in San Carlos, California, and currently collaborates with several prominent cancer centers and pharmaceutical companies.